Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus

Abstract

Women who carry a mutation in the BRCA1 gene (on chromosome 17q21), have an 80% risk of breast cancer and a 40% risk of ovarian cancer by the age of 70 (ref. 1). The variable penetrance of BRCA1 suggests that other genetic and non-genetic factors play a role in tumourigenesis in these individuals. The HRAS1 variable number of tandem repeats (VNTR) polymorphism, located 1 kilobase (kb) downstream of the HRAS1 proto-oncogene (chromosome 11p15.5 ) is one possible genetic modifier of cancer penetrance. Individuals who have rare alleles of this VNTR have an increased risk of certain types of cancers, including breast cancer2–4. To investigate whether the presence of rare HRAS1 alleles increases susceptibility to hereditary breast and ovarian cancer, we have typed a panel of 307 female BRCA1 carriers at this locus using a PCR-based technique. The risk for ovarian cancer was 2.11 times greater for BRCA1 carriers harbouring one or two rare HRAS1 alleles, compared to carriers with only common alleles (P = 0.015). The magnitude of the relative risk associated with a rare HRAS1 allele was not altered by adjusting for the other known risk factors for hereditary ovarian cancer5. Susceptibility to breast cancer did not appear to be affected by the presence of rare HRAS1 alleles. This study is the first to show the effect of a modifying gene on the penetrance of an inherited cancer syndrome.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Easton, D., Ford, D., Bishop, D. & Consortium, B.C.L. Breast and Ovarian cancer incidence in BRCA1- mutation carriers. Am. J. Hum. Genet. 56, 265–271 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lidereau, R. et al. High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J. Natl. Cancer Inst. 77, 697–701 (1986).

    Article  CAS  PubMed  Google Scholar 

  3. Krontiris, T., Devlin, B, Karp, D., Robert, N. & Risch, N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. New Eng. J. Med. 329, 517–523 (1993).

    Article  CAS  PubMed  Google Scholar 

  4. Garret, P., Hulka, B., Kim, Y. & Farber, R. HRAS protooncogene polymorphism and breast cancer. Cancer Epi. Biomarkers Prevention 2, 131–138 (1993).

    Google Scholar 

  5. Narod, S. et al. Risk modifiers in carriers of BRCA1 mutations. Int. J. Cancer 64, 394–398 (1995).

    Article  CAS  PubMed  Google Scholar 

  6. Simard, J. et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet. 8, 392–398 (1995).

    Article  Google Scholar 

  7. Serova, O. et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am. J. Hum. Genet. 58, 42–51 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Shattuck-Eidens, D. et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 273, 535–541 (1995).

    Article  CAS  PubMed  Google Scholar 

  9. Hogervorst, F. et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nature Genet. 10, 208–212 (1995).

    Article  CAS  PubMed  Google Scholar 

  10. Castilla, L. et al.Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer.. Nature Genet. 8, 387–391 (1995).

    Article  Google Scholar 

  11. Capon, D., Chen, E., Levinson, A., Seeburg, P. & Goeddel, D. Complete nucleotide sequence of the T24 human bladder carcinoma oncogene and it's normal homologue. Nature 302, 33–37 (1983).

    Article  CAS  PubMed  Google Scholar 

  12. Cox, D. Regression models and life tables. J. R. Stat Soc. 1972 34, 187–220 (1972).

    Google Scholar 

  13. Trepicchio, W. & Krontiris, T. Members of the rel/NF-kB family of transcriptional regulatory factors bind the HRAS1 minisatellite DNA sequence. Nucl. Acids Res. 20, 2427–2434 (1992).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Green, M. & Krontiris, T. Allelic variation of reporter gene activation by the HRAS1 minisatellite. Genomics 17, 429–434 (1993).

    Article  CAS  PubMed  Google Scholar 

  15. Spandidos, D. & Holmes, L. Transcriptional enhancer activity in the variable tandem repeat DNA sequence downstream of the human Ha-ras-1 gene. FEBS Lett. 218, 41–46 (1987).

    Article  CAS  PubMed  Google Scholar 

  16. Ryberg, D., Lindstedt, B., Zienolddiny, S. & Haugen, A. A herditary genetic marker closely associated with microsatellite instability in lung cancer.Cancer Res. 55, 3996–3999 (1995).

    CAS  PubMed  Google Scholar 

  17. Narod, S. et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am. J. Hum. Genet. 56, 254–264 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Decorte, R., Cuppens, H., Marynen, P. & Cassiman, J.-J. Rapid detection of hypervariable regions by the polymerase chain reaction technique. DNA Cell Biol. 9, 461–469 (1990).

    Article  CAS  PubMed  Google Scholar 

  19. Ardern, J. et al. Polymerase chain reaction analysis of allele frequency and loss at the Harvey Ras locus in myeloid malignancies. Leukemia 7, 258–262 (1993).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Phelan, C., Rebbeck, T., Weber, B. et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 12, 309–311 (1996). https://doi.org/10.1038/ng0396-309

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0396-309

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing